July 01, 2022
Article
Here is a rundown of the most popular and significant stories we covered this past week.
June 30, 2022
Antibody levels decline in individuals with hybrid immunity similarly to vaccinated individuals, meaning all people need a booster vaccine to protect against future, potentially severe, infection.
A computational framework for estimating vaccine effectiveness based on genetic differences of SARS-CoV-2 variants showed promising results in a new study that verified the model with clinical trial data.
June 29, 2022
In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.
June 28, 2022
After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.
June 27, 2022
Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.
June 26, 2022
Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.
June 24, 2022
Video
Dr. Heather Platt discusses the process of developing V116, a pneumococcal vaccine that targets the serotypes most prevalent in those 65 years and older.
June 23, 2022
Podcast
Listen to our interview with Sanofi vaccine expert Dr. Christopher Rizzo about what this preferential recommendation means, and why high-dose flu vaccines are needed for older adults.
June 19, 2022
Studies, advances, and authorizations continue in this paramount area within infectious disease.
Monkeypox Symptoms in London Patients Differ from Prior Outbreaks
How COVID-19 Infiltrates and Inflames the Heart
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Communities With More Racial Prejudice Have Worse Health Outcomes
